{"title": "Takeda-backed Ambys tops out series A with $47M more to test liver cell therapy in 2023", "author": "Kyle LaHucik", "url": "https://www.fiercebiotech.com/biotech/ambys-tops-out-series-a-47m-more-to-test-cell-therapy-liver-disease-2023", "hostname": "fiercebiotech.com", "description": "Takeda-backed Ambys Medicines has added $47 million to its series A | Ambys Medicines wants to go after diseases impacting the liver, a key regenerative organ, with cell therapies. The Takeda-partnered biotech snagged $47 million from the Japanese Pharma and venture shops to test its asset in human trials in 2023.", "sitename": "FierceBiotech", "date": "2021-12-21", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}